eXoZymes Inc.
EXOZ | NASDAQ
$4.11
-$0.20 (-4.64%)
At close: Nov 5, 2026, 4:00 PM ET
$4.15
+$0.04 (+0.97%)
After-hours:
Nov 5, 2026, 4:00 PM ET
Company Profile
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
Key Executives
| Name | Position |
|---|---|
| Michael Heltzen | President & Chief Executive Officer |
| Amy Lunzer | Chief of Staff |
| Damien A. Perriman | Chief Commercial Officer |
| Fouad Nawaz | Vice President of Finance |
| James U. Bowie | Founder & Independent Director |
| Lasse H. Gorlitz | Vice President of Communications |
| Michael Burns | Executive Vice President of Energy Transition |
| Paul Opgenorth | Co-Founder & Vice President of Development |
| Tyler Korman | Co-Founder & Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 28, 2026 | DEFA14A | Filing |
| Sep 28, 2026 | DEF 14A | Filing |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 25, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Jul 01, 2026 | 8-K | Current Report |
| Jun 30, 2026 | 424B5 | Filing |
eXoZymes Inc.
| Country | United States |
| IPO Date | Nov 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Michael Heltzen |
Contact Details
750 Royal Oaks Drive Monrovia,
California 91016 United States
Stock Details
| Ticker Symbol | EXOZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002010788 |
| CUSIP Number | 461874109 |
| ISIN Number | US4618741098 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove EXOZ